125 related articles for article (PubMed ID: 37151105)
1. Effect of 12-months testosterone replacement therapy on bone mineral density and markers of bone turnover in testicular cancer survivors - results from a randomized double-blind trial.
Jørgensen PL; Kreiberg M; Jørgensen N; Juul A; Oturai PS; Dehlendorff C; Lauritsen J; Wagner T; Rosenvilde J; Daugaard G; Medici CR; Jørgensen NR; Bandak M
Acta Oncol; 2023 Jul; 62(7):689-695. PubMed ID: 37151105
[TBL] [Abstract][Full Text] [Related]
2. A randomized double-blind single center study of testosterone replacement therapy or placebo in testicular cancer survivors with mild Leydig cell insufficiency (Einstein-intervention).
Kreiberg M; Jørgensen N; Juul A; Lauritsen J; Oturai P; Helge JW; Christensen JF; Aksglaede L; Schauer T; Wagner T; Rosenvilde J; Grunwald E; Dehlendorff C; Daugaard G; Bandak M
Clin Genitourin Cancer; 2022 Oct; 20(5):404-414. PubMed ID: 35701334
[TBL] [Abstract][Full Text] [Related]
3. Effect of Testosterone Replacement Therapy on Quality of Life and Sexual Function in Testicular Cancer Survivors With Mild Leydig Cell Insufficiency: Results From a Randomized Double-blind Trial.
Højer EG; Kreiberg M; Dehlendorff C; Jørgensen N; Juul A; Lauritsen J; Wagner T; Rosenvilde J; Daugaard G; Bandak M
Clin Genitourin Cancer; 2022 Aug; 20(4):334-343. PubMed ID: 35514022
[TBL] [Abstract][Full Text] [Related]
4. Insulin-like Factor 3, Basal and Human Chorionic Gonadotropin-Stimulated Testosterone as Biomarkers to Predict the Effect of Testosterone Replacement in Testicular Cancer Survivors With Mild Leydig Cell Insufficiency.
Medici C; Jørgensen N; Juul A; Albrethsen J; Kreiberg M; Lauritsen J; Wagner T; Rosenvilde J; Daugaard G; Bandak M
Clin Genitourin Cancer; 2024 Feb; 22(1):e106-e112.e4. PubMed ID: 37673783
[TBL] [Abstract][Full Text] [Related]
5. A randomized double-blind study of testosterone replacement therapy or placebo in testicular cancer survivors with mild Leydig cell insufficiency (Einstein-intervention).
Bandak M; Jørgensen N; Juul A; Lauritsen J; Kreiberg M; Oturai PS; Helge JW; Daugaard G
BMC Cancer; 2017 Jul; 17(1):461. PubMed ID: 28673265
[TBL] [Abstract][Full Text] [Related]
6. Romosozumab increases bone mineral density in postmenopausal Japanese women with osteoporosis: A phase 2 study.
Ishibashi H; Crittenden DB; Miyauchi A; Libanati C; Maddox J; Fan M; Chen L; Grauer A
Bone; 2017 Oct; 103():209-215. PubMed ID: 28687496
[TBL] [Abstract][Full Text] [Related]
7. Randomized placebo-controlled trial of testosterone replacement in men with mild Leydig cell insufficiency following cytotoxic chemotherapy.
Howell SJ; Radford JA; Adams JE; Smets EM; Warburton R; Shalet SM
Clin Endocrinol (Oxf); 2001 Sep; 55(3):315-24. PubMed ID: 11589674
[TBL] [Abstract][Full Text] [Related]
8. Impact of testosterone therapy on bone turnover markers in obese males with type 2 diabetes and functional hypogonadism.
Groti Antonič K
Aging Male; 2022 Dec; 25(1):269-277. PubMed ID: 36355053
[TBL] [Abstract][Full Text] [Related]
9. Twice-weekly teriparatide improves lumbar spine BMD independent of pre-treatment BMD and bone turnover marker levels.
Takada J; Yoshimura T; Uzawa T
J Bone Miner Metab; 2021 May; 39(3):484-493. PubMed ID: 33389132
[TBL] [Abstract][Full Text] [Related]
10. Effects of transdermal testosterone gel on bone turnover markers and bone mineral density in hypogonadal men.
Wang C; Swerdloff RS; Iranmanesh A; Dobs A; Snyder PJ; Cunningham G; Matsumoto AM; Weber T; Berman N
Clin Endocrinol (Oxf); 2001 Jun; 54(6):739-50. PubMed ID: 11422108
[TBL] [Abstract][Full Text] [Related]
11. Effects of growth hormone (GH) replacement on bone metabolism and mineral density in adult onset of GH deficiency: results of a double-blind placebo-controlled study with open follow-up.
Finkenstedt G; Gasser RW; Höfle G; Watfah C; Fridrich L
Eur J Endocrinol; 1997 Mar; 136(3):282-9. PubMed ID: 9100553
[TBL] [Abstract][Full Text] [Related]
12. Positive effect of alendronate on bone mineral density and markers of bone turnover in patients with rheumatoid arthritis on chronic treatment with low-dose prednisone: a randomized, double-blind, placebo-controlled trial.
Lems WF; Lodder MC; Lips P; Bijlsma JW; Geusens P; Schrameijer N; van de Ven CM; Dijkmans BA
Osteoporos Int; 2006; 17(5):716-23. PubMed ID: 16463007
[TBL] [Abstract][Full Text] [Related]
13. The effect of testosterone treatment on bone mineral density in Klinefelter syndrome: A retrospective cohort study.
Willems S; David K; Decallonne B; Marcq P; Antonio L; Vanderschueren D
Andrology; 2023 Oct; 11(7):1295-1302. PubMed ID: 36792918
[TBL] [Abstract][Full Text] [Related]
14. The effect of Cissus quadrangularis L. on delaying bone loss in postmenopausal women with osteopenia: A randomized placebo-controlled trial.
Benjawan S; Nimitphong H; Tragulpiankit P; Musigavong O; Prathanturarug S; Pathomwichaiwat T
Phytomedicine; 2022 Jul; 101():154115. PubMed ID: 35523116
[TBL] [Abstract][Full Text] [Related]
15. Observational Study to Evaluate the Effect of Epidural Steroid Injection on Bone Mineral Density and Bone Turnover Markers.
Jain A; Gupta P; Chaurasia R; Singh M; Pandey S
Pain Physician; 2020 Sep; 23(5):E517-E524. PubMed ID: 32967402
[TBL] [Abstract][Full Text] [Related]
16. Baseline bone turnover marker levels can predict change in bone mineral density during antiresorptive treatment in osteoporotic patients: the Copenhagen bone turnover marker study.
Bønløkke SE; Rand MS; Haddock B; Arup S; Smith CD; Jensen JEB; Schwarz P; Hovind P; Oturai PS; Jensen LT; Møller S; Eiken P; Rubin KH; Hitz MF; Abrahamsen B; Jørgensen NR
Osteoporos Int; 2022 Oct; 33(10):2155-2164. PubMed ID: 35729342
[TBL] [Abstract][Full Text] [Related]
17. Risk of low bone mineral density in testicular germ cell cancer survivors: association with hypogonadism and treatment modality.
Isaksson S; Bogefors K; Åkesson K; Egund L; Bobjer J; Leijonhufvud I; Giwercman A
Andrology; 2017 Sep; 5(5):898-904. PubMed ID: 28591464
[TBL] [Abstract][Full Text] [Related]
18. Testosterone replacement in congenital hypogonadotropic hypogonadism maintains bone density but has only limited osteoanabolic effects.
Antonio L; Caerels S; Jardi F; Delaunay E; Vanderschueren D
Andrology; 2019 May; 7(3):302-306. PubMed ID: 30851011
[TBL] [Abstract][Full Text] [Related]
19. Effects of risedronate 5 mg/d on bone mineral density and bone turnover markers in late-postmenopausal women with osteopenia: a multinational, 24-month, randomized, double-blind, placebo-controlled, parallel-group, phase III trial.
Välimäki MJ; Farrerons-Minguella J; Halse J; Kröger H; Maroni M; Mulder H; Muñoz-Torres M; Sääf M; Snorre Øfjord E
Clin Ther; 2007 Sep; 29(9):1937-49. PubMed ID: 18035193
[TBL] [Abstract][Full Text] [Related]
20. Relationship between P1NP, a biochemical marker of bone turnover, and bone mineral density in patients transitioned from alendronate to romosozumab or teriparatide: a post hoc analysis of the STRUCTURE trial.
Takada J; Dinavahi R; Miyauchi A; Hamaya E; Hirama T; Libanati C; Nakamura Y; Milmont CE; Grauer A
J Bone Miner Metab; 2020 May; 38(3):310-315. PubMed ID: 31707465
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
